Genpact Limited Stock Alpha and Beta Analysis
| G Stock | USD 50.14 0.79 1.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Genpact Limited. It also helps investors analyze the systematic and unsystematic risks associated with investing in Genpact over a specified time horizon. Remember, high Genpact's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Genpact's market risk premium analysis include:
Beta 0.55 | Alpha 0.23 | Risk 1.84 | Sharpe Ratio 0.13 | Expected Return 0.24 |
Genpact Quarterly Cash And Equivalents |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Genpact |
Genpact Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Genpact market risk premium is the additional return an investor will receive from holding Genpact long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Genpact. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Genpact's performance over market.| α | 0.23 | β | 0.55 |
Genpact expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Genpact's Buy-and-hold return. Our buy-and-hold chart shows how Genpact performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Genpact Market Price Analysis
Market price analysis indicators help investors to evaluate how Genpact stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Genpact shares will generate the highest return on investment. By understating and applying Genpact stock market price indicators, traders can identify Genpact position entry and exit signals to maximize returns.
Genpact Return and Market Media
The median price of Genpact for the period between Mon, Dec 16, 2024 and Sun, Mar 16, 2025 is 47.54 with a coefficient of variation of 9.1. The daily time series for the period is distributed with a sample standard deviation of 4.36, arithmetic mean of 47.9, and mean deviation of 3.88. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
| Genpact dividend paid on 23rd of December 2024 | 12/23/2024 |
1 | Disposition of 19540 shares by Michael Weiner of Genpact at 43.34 subject to Rule 16b-3 | 01/10/2025 |
2 | Disposition of 47972 shares by N Tyagarajan of Genpact at 43.34 subject to Rule 16b-3 | 01/17/2025 |
3 | Disposition of 13221 shares by Heather White of Genpact at 43.34 subject to Rule 16b-3 | 01/24/2025 |
4 | BlackRock, Inc. Reduces Stake in Genpact Ltd A Strategic Portfolio Adjustment | 02/05/2025 |
5 | Genpact Ltd Trading 10.87 percent Higher on Feb 7 | 02/07/2025 |
6 | How Is Genpact Expanding Its Digital Transformation Services | 02/11/2025 |
7 | Disposition of 4000 shares by Heather White of Genpact at 55.25 subject to Rule 16b-3 | 02/13/2025 |
8 | Disposition of 108880 shares by N Tyagarajan of Genpact at 54.87 subject to Rule 16b-3 | 02/20/2025 |
9 | The State of New Jersey Common Pension Fund D has announced a new investment in Genpact Limited . | 02/24/2025 |
10 | Heres Why Genpact is a Strong Growth Stock | 02/26/2025 |
11 | How Is Genpact Limited Performing Amid Institutional Adjustments | 02/27/2025 |
12 | Genpact Full Year 2024 Earnings EPS Beats Expectations | 03/05/2025 |
13 | Disposition of 1400 shares by Laura Conigliaro of Genpact subject to Rule 16b-3 | 03/07/2025 |
14 | Acquisition by Michael Weiner of 14587 shares of Genpact subject to Rule 16b-3 | 03/11/2025 |
15 | Contract Pharmaceutical Manufacturing Market Is Booming Worldwide 2025-2032 Lonza Group, Genpact Limited, Accenture plc | 03/12/2025 |
16 | Disposition of 13600 shares by Balkrishan Kalra of Genpact at 27.65 subject to Rule 16b-3 | 03/13/2025 |
17 | Why Genpact is a Top Growth Stock for the Long-Term | 03/14/2025 |
About Genpact Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Genpact or other stocks. Alpha measures the amount that position in Genpact Limited has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Dividend Yield | 0.0108 | 0.0158 | 0.0142 | 0.0234 | Price To Sales Ratio | 1.95 | 1.41 | 1.61 | 2.29 |
Genpact Upcoming Company Events
As portrayed in its financial statements, the presentation of Genpact's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genpact's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Genpact's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Genpact. Please utilize our Beneish M Score to check the likelihood of Genpact's management manipulating its earnings.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Genpact
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Genpact Backtesting, Genpact Valuation, Genpact Correlation, Genpact Hype Analysis, Genpact Volatility, Genpact History and analyze Genpact Performance. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Genpact technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.